Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, […]
Read MoreAutor: Firma Kuros Biosciences
Kuros Biosciences reports results for the first six months of 2022
Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA cleared MagnetOs Flex Matrix for spinal indications MagnetOs Easypack Putty launched in the US in […]
Read MoreAnnual General Meeting of Kuros Biosciences approves all resolutions
. Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board […]
Read MoreKuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals and within hospital systems Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today promising preliminary results from the […]
Read MoreKuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of MagnetOs Easypack Putty in the U.S., at the 22nd Annual Meeting of the International Society […]
Read MoreKuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine Promising first-in-human data from Phase II trial of Fibrin-PTH (KUR-113) in tibial fractures Milestone payment of $5 million to be received from Checkmate […]
Read MoreKuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization plans Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Flex Matrix has been cleared […]
Read MoreKuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other 510(k)-cleared bone grafts on the market Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs […]
Read MoreKuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH for spinal fusion Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the publication of first-in-human data from […]
Read MoreKuros Biosciences reports continued increase in MagnetOs U.S. sales
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in […]
Read More